XiaoMi-AI文件搜索系统
World File Search SystemVYALEV
用户指南.pdf
接受左旋多巴（VYALEV 的活性代谢物）治疗的患者报告称，他们在从事日常生活活动（包括驾驶机动车）时会睡着，有时会导致事故。尽管许多患者报告称，服用左旋多巴时会出现嗜睡，但有些患者认为自己没有任何警示信号，例如过度嗜睡，并认为自己在事件（睡眠发作）发生前是清醒的。有些事件是在开始治疗一年多后报告的。因此，处方医生应持续评估接受 VYALEV 治疗的患者是否嗜睡或困倦。告知患者服用 VYALEV 可能会出现嗜睡，并询问可能增加嗜睡风险的因素。如果患者报告称，在需要主动参与的活动中白天嗜睡或入睡，请考虑停用 VYALEV。如果继续使用 VYALEV，应建议患者不要开车，并避免其他可能造成伤害的潜在危险活动。没有足够的信息证明减少剂量会消除日常生活活动中入睡的现象。
AR Medicaid事先授权在2025年1月15日的AR Medicaid DUR董事会会议上批准批准
来自：Cynthia neuhofel，Pharm.D。 Division of Medical Services Pharmacy Program DATE: February 12, 2025 SUBJ: AR Medicaid Prior Authorization Edits approved at the AR Medicaid DUR Board January 15, 2025 meeting for the following: Preferred Drug List Full Review: Glucagon agents, GLP-1 agonists, uterine disorder agents, Duchenne Muscular Dystrophy agents, ulcerative colitis agents Preferred Drug List Abbreviated Review: Alpha glucosidase inhibitors, DPP-4 inhibitors, meglitinides, metformin products, SGLT-2 inhibitors, sulfonylureas, thiazolidinediones, amylin analogues, antiemetics, non-sedating antihistamines, intranasal rhinitis Manual Review PA Criteria: Nemluvio® (nemolizumab-ilto), Miplyffa™ (arimoclomol citrate), Aqneursa™ (levacetylleucine), Hympavzi™ (marstacimab-hncq), Vyalev™ (foscarbidopa/foslevodopa), Duvyzat™ (givinostat), Lodoco® (colchicine), Yorvipath® (palopegteriparatide), FUROSCIX®（FUOSEMIDE）更新：在PA标准文档中清理手册评论药物，更新常规药物策略来自：Cynthia neuhofel，Pharm.D。Division of Medical Services Pharmacy Program DATE: February 12, 2025 SUBJ: AR Medicaid Prior Authorization Edits approved at the AR Medicaid DUR Board January 15, 2025 meeting for the following: Preferred Drug List Full Review: Glucagon agents, GLP-1 agonists, uterine disorder agents, Duchenne Muscular Dystrophy agents, ulcerative colitis agents Preferred Drug List Abbreviated Review: Alpha glucosidase inhibitors, DPP-4 inhibitors, meglitinides, metformin products, SGLT-2 inhibitors, sulfonylureas, thiazolidinediones, amylin analogues, antiemetics, non-sedating antihistamines, intranasal rhinitis Manual Review PA Criteria: Nemluvio® (nemolizumab-ilto), Miplyffa™ (arimoclomol citrate), Aqneursa™ (levacetylleucine), Hympavzi™ (marstacimab-hncq), Vyalev™ (foscarbidopa/foslevodopa), Duvyzat™ (givinostat), Lodoco® (colchicine), Yorvipath® (palopegteriparatide), FUROSCIX®（FUOSEMIDE）更新：在PA标准文档中清理手册评论药物，更新常规药物策略